Condition

Adenocarcinoma Gastric (2)

Esophageal Cancer (1)

Gastric Cancer (1)

GastroEsophageal Cancer (1)

Gastrooesophageal Cancer (1)

HER2 Positive Gastric Cancer (1)

Metastatic Gastric Cancer (1)

Overall Status

Completed (1)

Recruiting (1)

Sign in for free

Phase

phase 2 (2)

Sponsor

AIO-Studien-gGmbH (1)

Sanofi (1)

Collaborator

Bristol-Myers Squibb (1)

Intervention

ipilimumab (1)

nivolumab (1)

ramucirumab (cyramza®) (1)

tusamitamab ravtansine (sar408701) (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (1)

Other (1)

Study Type

Interventional (2)

adenocarcinoma gastric

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Adenocarcinoma Gastric, Gastrooesophageal Cancer Trial in Worldwide (Ramucirumab (CYRAMZA®), Tusamitamab ravtansine (SAR408701))

Recruiting

Adenocarcinoma Gastric
Gastrooesophageal Cancer

Ramucirumab (CYRAMZA®)
Tusamitamab ravtansine (SAR408701)

Bruxelles, Belgium
+22 more

Jan 16, 2023

Gastric Cancer, Esophageal Cancer, Adenocarcinoma Gastric Trial in Germany (Nivolumab, Ipilimumab)

Completed

Gastric Cancer
+5 more

Amberg, Germany
+34 more

May 17, 2022